This month has been lousy, but there are factors that could still produce a year-end rally.
There is much talk that IBM is overpaying for Red Hat, but this deal is a net positive for the market as a whole.
This name has significantly outperformed both the S&P 500 and the health care sector over the course of this awful month
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
There is clear divergence between the best and the worst performers in each sector this earnings season.
There have been some solid earnings reports, but they haven't provided a boost to the broader market.
Cannabis and tobacco are hard to equate, which Barclays' primer on the Cannabis industry misses.
Danaher reports its ninth straight earnings beat.
But don't buy into this overheated market right as Canada legalizes, wait until prices come down -- which they will.
Big-picture concerns are intensifying selling pressure, which favors bargain hunters in search of individual stocks.